AllSci News
Ionis signs ex-US zilganersen licensing deal with Recordati ahead of FDA decision
Ionis locks in a USD 30 million upfront payment and tiered royalties of up to the mid-20% range from Italy-based Recordati (Milan: REC) for exclusive ex-US...
Pfizer expands Ibrance into HER2-positive breast cancer with first CDK4/6 maintenance win
The US FDA approved Ibrance (palbociclib) for a new indication in HR-positive, HER2-positive metastatic breast cancer, marking Pfizer’s first regulatory success for…
FDA approves Ionis’ Tryngolza to cut acute pancreatitis risk in hypertriglyceridemia
The US FDA has approved Tryngolza (olezarsen) — making it the first therapy demonstrated to reduce the risk of acute pancreatitis in…
CeleCor seeking approval for zalunfiban as first antiplatelet therapy for pre-hospital STEMI care
Del Mar, California-based CeleCor Therapeutics has completed submission of a New Drug Application (NDA) to the US FDA for Disaggpro (zalunfiban), an...
Sangamo files for bankruptcy as Lilly and Astellas become stalking horse bidders for gene therapy assets
Richmond, California-based Sangamo Therapeutics, Inc. (OTCQB: SGMO) has entered into two separate asset sale agreements with Eli Lilly and Astellas Pharma,...
Duke University launches multiscale immune systems modeling center to link molecular dynamics with population-level disease outcomes
Duke University has received a USD 4.8 million NIAID U54 award to establish a Center for Multiscale Immune Systems Modeling, reflecting sustained federal...
Vellum Biotechnology develops electrophoresis-based method to unlock nucleic acids from archived tissue samples
Palo Alto-based Vellum Biotechnology, Inc. has received a USD 1.01 million NIH SBIR R44 grant from the National Human Genome Research Institute to develop...
CalciMedica pivots toward pulmonary hypertension with USD 49m financing round
La Jolla, California-based CalciMedica, Inc. (Nasdaq: CALC) announced a private placement of up to approximately USD 49 million to pivot the company's...
MoonLake boosts public offering to USD 200m for sonelokimab
Switzerland-based MoonLake Immunotherapeutics (Nasdaq: MLTX) announced the pricing of an upsized underwritten public offering of Class A ordinary shares and...
uniQure upsizes public offering to USD 225m
Lexington, Massachusetts-based uniQure N.V. (Nasdaq: QURE) announced the pricing of an upsized underwritten public offering of ordinary shares, raising USD...
AECOM investigates novel protein-RNA interaction to block and lock HIV-1 latency
Albert Einstein College of Medicine has received a USD 3.2 million NIH R01 grant from the National Institute of Allergy and Infectious Diseases to...
Yale investigates immune mechanisms driving celiac disease to find new therapies and biomarkers
Yale University has received a USD 2.3 million NIAID P01 program project grant to investigate the immunopathogenesis of celiac disease, with a dual focus on...
Tulane Uni investigates CD4+ T cell immunity to improve pneumonia vaccines
Tulane University has received a USD 1.09 million NIH R35 award from the National Heart, Lung, and Blood Institute to investigate CD4+ T cell immunity in...
Trimtech raises USD 47m for TRIM21-targeted protein degradation in neurodegeneration
UK-based TRIMTECH Therapeutics has closed an additional USD 14 million in seed funding, bringing its total seed round to USD 47 million (£35 million), as...
Rapalogix secures USD 20m to advance TORC1-targeting skincare and prescription dermatology pipeline
Carlsbad, California-based Rapalogix Health, a biotechnology company developing TORC1-targeting therapeutics and professional skincare products for skin...
The AllSci Brief
Systematic R&D and deal news. Daily.